Acelyrin Inc SLRN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SLRN is a good fit for your portfolio.
News
-
ACELYRIN ALERT: Bragar Eagel & Squire, P.C. is Investigating Acelyrin, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
-
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
-
ACELYRIN, INC. Announces Leadership Transition
-
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
-
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
-
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
-
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
-
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
Trading Information
- Previous Close Price
- $4.63
- Day Range
- $4.37–4.68
- 52-Week Range
- $4.14–29.88
- Bid/Ask
- $4.39 / $5.36
- Market Cap
- $434.73 Mil
- Volume/Avg
- 742,134 / 1.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of of transformative medicines.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 130
- Website
- https://www.acelyrin.com
Comparables
Valuation
|
Metric
|
SLRN
|
LYEL
|
VOR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.71 | 1.16 | 1.00 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SLRN
|
LYEL
|
VOR
|
|---|---|---|---|
Quick Ratio | 13.08 | 15.82 | 8.13 |
Current Ratio | 13.27 | 16.07 | 8.46 |
Interest Coverage | — | — | — |
Quick Ratio
SLRN
LYEL
VOR
Profitability
|
Metric
|
SLRN
|
LYEL
|
VOR
|
|---|---|---|---|
Return on Assets (Normalized) | −28.15% | −21.31% | −48.29% |
Return on Equity (Normalized) | −35.30% | −24.24% | −61.06% |
Return on Invested Capital (Normalized) | −41.97% | −25.73% | −54.20% |
Return on Assets
SLRN
LYEL
VOR
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dpthjqmbs | Fljb | $586.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Sfmxbkwf | Bwnftlj | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dgdqvnvzb | Cyxpy | $108.2 Bil | |
MRNA
| Moderna Inc | Xxfkdfgdv | Scq | $50.9 Bil | |
ARGX
| argenx SE ADR | Pcwxgthzd | Lktj | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Fhkvhrj | Dnmj | $21.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dcklrvfgp | Zzyhj | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jhpcsbcgd | Btkthyh | $14.6 Bil | |
INCY
| Incyte Corp | Fsbpkvff | Cyjfz | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wdjcdxpfh | Nlmsvw | $12.3 Bil |